Lucas was branded as a mutant with an M-shaped mark on his face around his right eye; he enlisted in X.S.E (Xavier’s Security Enforcement), a police force created to bring the world back to normal, ...

Kevin Feige has a 10-year plan for the X-Men following the two upcoming Avengers movies. Writer Michael Lesslie has been tapped to work on a script for an MCU movie that will come after Avengers ...

GameSpot may get a commission from retail offers.

Super Evil Megacorp will release roguelike action game Teenage Mutant Ninja Turtles: Splintered Fate for PlayStation 5 and PlayStation 4 May 20, followed by Xbox Series and Xbox One on June 24 ...

Cannes Ketchup – Day 3: A Unanimous Rave, a Divisive Fave, and More Link to Cannes Ketchup – Day 3: A Unanimous Rave, a Divisive Fave, and More The 10 Best Deaths of the Final Destination ...

This study presents and characterizes a Dnmt3a mutant mouse model which carries a heterozygous hotspot R878H mutation frequently found in human cancers, providing insights into Dnmt3a-mutant ...

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, including TKD and non-TKD mutations. Activity with zongertinib was observed in ...

Itziar Canamasas, Global Head of Oncology at Boehringer Ingelheim, said: "Zongertinib has the potential to reset the benchmark for patients with HER2-mutant advanced non-small cell lung cancer, a ...

Enhertu nabbed that accelerated FDA approval as the first HER2-directed med for patients with previously treated HER2-mutant metastatic NSCLC, back in 2022. The data for that green light came from ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

Introduction: K-ras mutant lung adenocarcinoma (KM-LUAD) is a difficult-to-treat cancer subtype in which chronic inflammation pervades the tumor immune microenvironment (TIME). Pro-inflammatory ...

“There is a high unmet need for new treatments within this patient population as there are currently no targeted therapies approved for any RAS G12D mutant cancer,” said Kathryn ...